- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04025320
The Effect of Intraneural Facilitation Therapy on Diabetic Patients With Peripheral Neuropathy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Loma Linda, California, United States, 92350
- Loma Linda University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with Diabetes Type 2 and Diabetic Peripheral Neuropathy with no other known underlying disease
- Below ankle Diabetic Peripheral Neuropathy symptoms (numbness, tingling, burning, sharp pain, increased sensitivity, etc.)
- ≥10 on Quality of Life- Diabetic Neuropathy Scale (QOL- DN)
- Between age 50-75 years
Exclusion Criteria:
- Patients with a medical condition that suggested possible decline in function over the next 6 months such as; a current regimen of chemotherapy, radiation therapy, or dialysis
- Any lower extremity amputations or wounds
- Documented active alcohol and/or drug misuse
- Known health conditions: end stage renal failure, uncontrolled hypertension, severe dyslipidemia, chronic liver disease, autoimmune disease, advanced chronic obstructive pulmonary disease and active inflammations
- DM patients with inflammatory neuropathies including chronic inflammatory demyelinating polyneuropathy (CIDP), proximal diabetes neuropathy, and autonomic neuropathies
- Patients with other types of neuropathies not associated with Diabetes Mellitus such as B12 deficiency, hypothyroidism, and uremia
- Other severe chronic medical condition requiring active treatment
- Morbidly Obese patients
- Pregnancy (self reported)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Intraneural facilitation treatment for 50-60 minutes. 50 minutes if ultrasound received. 9 total treatment visits, 3 visits per week • One 50-60 minute visit on Monday, Wednesday and Friday, for 3 weeks. |
Intraneural Facilitation utilizes three manual holds.
Firstly, the contralateral joint is placed in a maximal loose-pack position to pressurize the nervous system and bias circulation from the artery into the epineurium.
Now that we have increased this pressure we begin the secondary hold to bias the increased epineurial blood into the transperineurial vessels that bridge the epiperineum and the endoneurial capillaries of the site being treated.
Now that the pressure has increased into the open endoneurial capillaries, the goal is to open up ischemic endoneurial capillaries and this is hypothesized to open by providing the third hold.
The third hold is known as the sub hold and encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of bernoulli's principle.
This treatment will take 50-60 minutes.
|
Sham Comparator: Group 2
SHAM treatment for 50-60 minutes. 50 minutes if ultrasound received. 9 total treatment visits, 3 visits per week • One 50-60 minute visit on Monday, Wednesday and Friday, for 3 weeks. |
A physical therapist will perform the SHAM light therapy at the same site as the INF therapy location, at the Neuropathic Treatment Center.
The SHAM light therapy will last 50-60 minutes and consists of using an anodyne unit for application of near-infrared light therapy.
The unit will not be switched on, but the pads will be placed on the subject and the subject will be blinded to the unit being on.
The anodyne therapy pads will be placed in the following locations on the affected lower limb: two on the plantar aspect of the foot in a T formation and one pad on the medial and lateral side of the calf.
A double folded towel will be wrapped around the subject's foot at the electrode sites to blind the subject's from the light not emitting from the electrodes, due to the anodyne unit being off.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Quality Assessment Scale
Time Frame: change between baseline and 5 weeks
|
It is a self-report tool derived from Neuropathic Pain Scale to evaluate the quality of neuropathic pain.
After reading the introduction of the questionnaire, subjects will then measure their pain on a numeric scale 0= "no pain" or "no painful sensation" to 10 = "worst imaginable pain sensation" .
A zero score represents the best outcome and a 10 is the worst outcome.
This questionnaire takes approximately 10 minutes.
|
change between baseline and 5 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Limits of Stability
Time Frame: change between baseline and 5 weeks
|
The LOS test will assess the subjects weight-shifting ability and voluntary limits of stability to eight directional targets set at 100% of theoretical limits of stability for an eight second hold.
The LOS test measures five parameters: reaction time, movement velocity, end point excursion, maximum excursion, and directional control.
We will take the composite scores of reaction time, movement velocity, end point excursion, maximum excursion, and directional control from the 8 directions.
This test should take 10 minutes.
|
change between baseline and 5 weeks
|
Zeno Walkway
Time Frame: change between baseline and 5 weeks
|
The Zeno Walkway is used to observe the spatiotemporal characteristics of gait in the subjects: velocity and stride length.
Participants will be wearing their own shoes and will be instructed prior to arrival to wear comfortable shoes without heels.
The subjects will be asked to walk back and forth the walkway 4 times.
This test will take 5 minutes.
|
change between baseline and 5 weeks
|
Sensory organization test (SOT)
Time Frame: change between baseline and 5 weeks
|
The SOT will assess the subject's use of visual, somatosensory, and vestibular systems for maintaining upright posture. The standardized test instructions, per NeuroCom protocol, were either "stand quietly with your eyes open" or "stand quietly with your eyes closed" depending on the condition being tested. This test is completed under six different sensory conditions lasting 20 seconds each.
|
change between baseline and 5 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lee Berk, DrPH, Loma Linda University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5190128
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Neuropathy
-
Tanta UniversityCompletedDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Painful Diabetic Neuropathy | Autonomic Neuropathy | Diabetic Polyneuropathy | Small Fiber NeuropathyEgypt
-
Imperial College LondonActegy Ltd.Not yet recruitingDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Diabetic Polyneuropathy | Diabetic ComplicationUnited Kingdom
-
University of PlymouthNot yet recruitingDiabetic Peripheral Neuropathy | Painful Diabetic Neuropathy
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
AbbVie (prior sponsor, Abbott)CompletedDiabetic Neuropathies | Diabetic Neuropathy, Painful | Diabetic Polyneuropathy | Diabetic Neuralgia | Neuralgia, DiabeticUnited States, Canada, France, Germany, Italy, Mexico, Puerto Rico
-
Tanta UniversityActive, not recruiting
-
October 6 UniversityCompletedDiabetic Neuropathy PeripheralEgypt
-
Power Life Sciences Inc.Not yet recruitingDiabetic Neuropathies | Diabetic Neuropathy Peripheral
-
Khyber Medical University PeshawarActive, not recruitingPeripheral Diabetic NeuropathyPakistan
Clinical Trials on Intraneural Facilitation
-
Loma Linda UniversityCompletedCarpal Tunnel SyndromeUnited States
-
Loma Linda UniversityRecruitingPeripheral Neuropathy With Type 2 DiabetesUnited States
-
Loma Linda UniversityRecruitingDiabetic Neuropathy, Distal Symmetric Polyneuropathy (Manifestation)United States
-
University of MinnesotaNot yet recruiting
-
VA Office of Research and DevelopmentCompleted
-
South Central VA Mental Illness Research, Education...CompletedDepressionUnited States
-
Noctem, LLCUnited States Department of Defense; Naval Health Research Center; US Air Force... and other collaboratorsActive, not recruitingChronic Insomnia | Implementation; Digital HealthUnited States
-
Northwestern UniversityUniversity of Utah; Pastors 4 PCORNot yet recruitingHypertensionUnited States
-
University of MichiganNational Institute of Mental Health (NIMH)TerminatedDepression | Bipolar Disorder | Mood DisorderUnited States
-
University Hospital, Basel, SwitzerlandCompleted